People: Cubist Pharmaceuticals Inc (CBST.O)


CBST.O on Nasdaq

50.73USD
1:14pm EDT
Price Change (% chg)

$-0.40 (-0.78%)
Prev Close
$51.13
Open
$51.10
Day's High
$51.10
Day's Low
$50.51
Volume
264,789
Avg. Vol
857,086
52-wk High
$56.68
52-wk Low
$36.73

Search Stocks

Summary

Name Age Since Current Position

Kenneth Bate

 62 2011 Non-Executive Independent Chairman of the Board

Robert Perez

 48 2012 President, Chief Operating Officer

Michael Bonney

 54 2012 Chief Executive Officer, Director

Michael Tomsicek

 47 2013 Chief Financial Officer, Senior Vice President

Steven Gilman

 60 2010 Executive Vice President - Research and Development, Chief Scientific Officer

Thomas DesRosier

 58 2013 Senior Vice President, General Counsel, Secretary

Patrick Vink

 50 2012 Senior Vice President, General Manager - International Business

Charles Laranjeira

 47 2011 Senior Vice President - Technical Operations

Gregory Stea

 55 2009 Senior Vice President - Commercial Operations

Mark Corrigan

 55 2008 Independent Director

Jane Henney

 66 2012 Independent Director

Nancy Hutson

 63 2008 Independent Director

Alison Lawton

 51 2012 Independent Director

Leon Moulder

 55 2010 Independent Director

Martin Rosenberg

 67 2005 Independent Director

J. Matthew Singleton

 60 2003 Independent Director

Martin Soeters

 59 2006 Independent Director

Michael Wood

 69 2005 Independent Director

Eileen McIntyre

 Vice President, Investor Relations
» Insider Trading

Biographies

Name Description

Kenneth Bate

 Mr. Kenneth M. Bate is Non-Executive Independent Chairman of the Board of Cubist Pharmaceuticals, Inc. Mr. Bate has served as one of Company's directors since June 2003 and became Company's Non-Executive Chair on March 2011, after serving as lead director since June 2006. Mr. Bate is currently an independent consultant. From May 2009 until January 2012, Mr. Bate served as President and Chief Executive Officer of Archemix Corp., or Archemix, a privately-held biotechnology company. From January 2007 to April 2009, Mr. Bate was President and Chief Executive Officer of NitroMed, Inc., or NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr. Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From January 2005 to March 2006, Mr. Bate was employed at JSB Partners, a firm that provides banking and advisory services to biopharmaceutical companies, which he co-founded. From 2002 to January 2005, Mr. Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., or Millennium, a public biopharmaceutical company. Mr. Bate is a director of two public biopharmaceutical companies, AVEO Pharmaceuticals, Inc., or AVEO, and BioMarin Pharmaceuticals, Inc., or BioMarin. During the last five years, Mr. Bate has served as a director of NitroMed and Coley Pharmaceutical Group, Inc., or Coley, a biopharmaceutical company, which was a public company during the period of Mr. Bate's service.

Robert Perez

 Mr. Robert J. Perez is President and Chief Operating Officer of Cubist Pharmaceuticals, Inc. Mr. Perez has been Cubist’s Executive Vice President and Chief Operating Officer since August 2007. Prior to this, he was Cubist’s Senior Vice President, Commercial Operations since July 2004. From August 2003 to July 2004, he served as Cubist’s Senior Vice President, Sales and Marketing. Mr. Perez serves on the board of AMAG Pharmaceuticals, Inc. Mr. Perez is a member of the Board of Advisors of Citizen Schools of Massachusetts and a director of the Biomedical Science Careers Program (BSCP).

Michael Bonney

 Mr. Michael W. Bonney is Chief Executive Officer, Director of Cubist Pharmaceuticals, Inc. From January 2002 to June 2003, he served as company's President and Chief Operating Officer. Mr. Bonney is a director of NPS Pharmaceuticals, Inc., or NPS, a public pharmaceutical company. He is Chair of the Bates College Board of Trustees. Mr. Bonney is also a board member of the Pharmaceutical Research and Manufacturers of America, or PhRMA, a non-profit pharmaceutical trade organization, and is a former board member of the Biotechnology Industry Organization, or BIO, Health Section Governing Body, a non-profit biotechnology trade organization.

Michael Tomsicek

 Mr. Michael Tomsicek is Chief Financial Officer, Senior Vice President of Cubist Pharmaceuticals, Inc., since March 2013. He served as Senior Vice President and Deputy Chief Financial Officer from July 2012 to March 2013. From August 2010 to July 2012, Mr. Tomsicek was Vice President, Corporate Finance and Treasurer. Before joining the company, Mr. Tomsicek served for eight years holding roles of increasing responsibility within the Healthcare unit of General Electric, or GE, a public global infrastructure and financial services company. His service at GE culminated in his role first as Chief Financial Officer of the Diagnostic Ultrasound business and finally Chief Financial Officer of the Global Ultrasound product group. Prior to that, Mr. Tomsicek was Manufacturing Finance Manager for the GE Healthcare Monitoring Systems business and was selected for and completed the GE Experienced Financial Leadership Program. Mr. Tomsicek also held various advancing roles in financial planning and channel management over seven years in the Automotive division of Motorola, then a public global telecommunications company. Following graduation from the University of Wisconsin with a Bachelor of Science degree in Industrial Engineering, Mr. Tomsicek began his career in manufacturing consulting for a Boston area start-up company after which he received his M.B.A., also from the University of Wisconsin.

Steven Gilman

 Dr. Steven C. Gilman, Ph.D., is Executive Vice President - Research and Development, Chief Scientific Officer of Cubist Pharmaceuticals, Inc., since September 2010. Prior to this, he served as Senior Vice President, Discovery & Nonclinical Development and Chief Scientific Officer from February 2008 to September 2010. From April 2007 until February 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics. From 2004 to April 2007, he served as President, Chief Executive Officer, and a member of the Board of Directors of ActivBiotics. Dr. Gilman serves on the Boards of Directors of the Massachusetts Biotechnology Council and Inhibikase Therapeutics, Inc. (a privately held biotechnology company) and serves on the Pennsylvania State University Biotechnology Advisory Board.

Thomas DesRosier

 Mr. Thomas DesRosier, J.D., is Senior Vice President, Chief Legal Officer, General Counsel and Secretary of Cubist Pharmaceuticals, Inc., since March 2013. Prior to joining Cubist, he served as Senior Vice President, General Counsel North America of Sanofi, a global biopharmaceutical company, a position he assumed following the acquisition by Sanofi of Genzyme Corporation, a global biopharmaceutical company, in 2011. Prior to that, he served as Chief Legal Officer of Genzyme from 2008 to 2011 and Senior Vice President and General Counsel of Genzyme from 2002 to 2008. Mr. DesRosier joined Genzyme in 1999 as Senior Vice President and Chief Intellectual Property Counsel. Before he joined Genzyme, Mr. DesRosier was Assistant General Counsel for patents at American Home Products Corp., then a public pharmaceutical company. Mr. DesRosier also served as Vice President and Chief Patent Counsel for Genetics Institute Inc., then a public biotechnology company, and held several intellectual property positions at E.I. DuPont de Nemours and Company, a global science company.

Patrick Vink

 Dr. Patrick Vink, M.D., has been appointed as Senior Vice President, General Manager - International Business of Cubist Pharmaceuticals, Inc., effective September 04, 2012. Dr. Vink brings 25 years of global industry experience to Cubist, most recently serving as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink coordinated all hospital business of the company. He joined Mylan in 2008, and established the company's operations in Switzerland, which was the basis of a number of global functions. Dr. Vink was also responsible for the company's biosimilars market entry. Prior to Mylan, Dr. Vink held several leadership positions across the industry, including Head of Business Franchise Biopharmaceuticals for Novartis Sandoz; Director, Central Europe and VP International Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthelabo. Dr. Vink received his doctorate of medicine from the University of Leiden in the Netherlands and an MBA from Erasmus University/William E. Simon School.

Charles Laranjeira

 Mr. Charles Laranjeira is Senior Vice President - Technical Operations of Cubist Pharmaceuticals Inc., since June 2011. Prior to that, Mr. Laranjeira served as Bristol-Myers Squibb's, or BMS's, Vice President of Latin America, Asia Pacific & Japan from July 2009 to February 2011, where he was responsible for regional operations management and product supply management to all markets within those regions. Prior to that, Mr. Laranjeira was BMS's Vice President of Asia Pacific and Japan from March 2008 to July 2009, and Vice President & General Manager from January 2003 to March 2008. His earlier positions with BMS include roles of responsibilities in technical operations, manufacturing, and industrial engineering in Spain, Australia, and the U.S.

Gregory Stea

 Mr. Gregory Stea is Senior Vice President - Commercial Operations of Cubist Pharmaceuticals, Inc., since February 2009. Prior to that, he served as Vice President, Sales and Marketing from September 2007 to February 2009. Previously, Mr. Stea served as Vice President, Sales from July 2005 to August 2007.

Mark Corrigan

 Dr. Mark H. Corrigan, M.D., is Independent Director of Cubist Pharmaceuticals, Inc., since June 2008. Since January 2010, Dr. Corrigan has served as President and Chief Executive Officer of Zalicus Inc. (formerly known as CombinatoRx, Incorporated), or Zalicus, a public biopharmaceutical company. He is also a member of the Board of Directors of Zalicus. From April 2003 to December 2009, Dr. Corrigan was Executive Vice President, Research and Development at Sepracor, Inc., or Sepracor, a public pharmaceutical company.

Jane Henney

 Dr. Jane E. Henney, M.D., is Independent Director of Cubist Pharmaceuticals, Inc., since March 2012. Dr. Henney is a Professor of Medicine at the University of Cincinnati College of Medicine and has served in that position since January 2008. From July 2003 to January 2008, she served as Senior Vice President and Provost of the University of Cincinnati's Academic Health Center. Dr. Henney was Senior Scholar at the Association of Academic Health Centers from 2001 to 2003 and Commissioner of the United States Food and Drug Administration, or FDA, from 1998 to 2001. Prior to that, Dr. Henney held the position of Vice President for Health Sciences at the University of New Mexico from 1994 to 1998 and Deputy Commissioner of Operations at the FDA from 1992 to 1994. Dr. Henney is a medical oncologist and has held several positions at the National Cancer Institute, including Deputy Director from 1980 to 1985. Dr. Henney also serves as a director of AmerisourceBergen Corporation, or AmerisourceBergen, and CIGNA Corporation, or CIGNA, both public global healthcare companies.

Nancy Hutson

 Dr. Nancy J. Hutson, Ph.D., is Independent Director of Cubist Pharmaceuticals Inc., since June 2008. Dr. Hutson retired from Pfizer Inc., or Pfizer, a global biopharmaceutical company, in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories. Dr. Hutson is also a director at Endo Pharmaceuticals Holdings Inc., or Endo, a public healthcare solutions company, and BioCryst Pharmaceuticals, Inc., or BioCryst, a public biotechnology company.

Alison Lawton

 Ms. Alison Lawton is Independent Director of Cubist Pharmaceuticals, Inc., since February 15, 2012. Since April 2010, Ms. Lawton has served as Senior Vice President, General Manager of Genzyme Biosurgery, a business unit of Genzyme Corporation, or Genzyme, which was acquired by Sanofi, each a global biopharmaceutical company, in April 2011. From May 2008 to April 2010, Ms. Lawton served as Senior Vice President, Global Market Access at Genzyme. From November 2005 to April 2008, Ms. Lawton served as Senior Vice President, Global Regulatory Affairs, Corporate Quality Systems and Global Policy Programs at Genzyme. From 2000 to November 2005, Ms. Lawton served as Senior Vice President, Global Regulatory Affairs and Corporate Quality Systems at Genzyme. Prior to that, since 1991, Ms. Lawton served in roles of increasing responsibility at Genzyme.

Leon Moulder

 Mr. Leon O. Moulder, Jr., is Independent Director of Cubist Pharmaceuticals, Inc., since February 2010. Since June 2010, Mr. Moulder has served as Chief Executive Officer of TESARO, Inc., or TESARO, a private biopharmaceutical company. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman, President and Chief Executive Officer of Abraxis BioScience, Inc., or Abraxis, a public biotechnology company, and as President and Chief Executive Officer of Abraxis's wholly-owned operating subsidiary, Abraxis BioScience, LLC, or Abraxis LLC, and the Abraxis Oncology division. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America, or Eisai, a pharmaceutical company and wholly-owned subsidiary of Eisai Co., Ltd., a public healthcare company, from January 2008 until January 2009, after Eisai acquired MGI PHARMA, Inc., a public biopharmaceutical company, or MGI PHARMA, where he served as President and Chief Executive Officer since May 2003. Mr. Moulder serves as director of Trevena, Inc., or Trevena, a private pharmaceutical company. Mr. Moulder also serves on the Board of Visitors of the Temple University School of Pharmacy.

Martin Rosenberg

 Dr. Martin Rosenberg, Ph.D., is Independent Director of Cubist Pharmaceuticals, Inc., since March 2005. Since 2003, Dr. Rosenberg has been the Chief Scientific Officer of Promega Corporation, or Promega, a private company providing services to the life sciences industry. Dr. Rosenberg is a director of Promega and Scarab Genomics L.L.C., or Scarab, a private biotechnology company. He also served as a member of the Advisory Council for the National Institutes of Allergy & Infectious Diseases at the National Institutes of Health for five years.

J. Matthew Singleton

 Mr. J. Matthew Singleton, CPA, is Independent Director of Cubist Pharmaceuticals, Inc., since June 2003. In October 2011, Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir (formerly CitationShares LLC), a private jet services company and wholly-owned subsidiary of Cessna Aircraft Company, which is owned by Textron Inc., a public industrial conglomerate. He served in this position since 2000. During the last five years, Mr. Singleton has served as a director of Salomon Reinvestment Company Inc., a private investment services company.

Martin Soeters

 Mr. Martin H. Soeters is Independent Director of Cubist Pharmaceuticals Inc., since September 2006. Since 1980, Mr. Soeters has worked at Novo Nordisk, a public global healthcare company located in Copenhagen, Denmark. Since 2008, Mr. Soeters has served as President of Novo Nordisk Europe A/S. From 2000 to 2007, Mr. Soeters served as President, North America and Senior Vice President of Novo Nordisk, Inc. He is also a member of the European Federation of Pharmaceuticals Industries and Associations (EFPIA) Heads of Europe, or EFPIA, a European pharmaceutical trade organization. During the last five years, Mr. Soeters has served as a director of Pharmacopeia, Inc., or Pharmacopeia, a public biopharmaceutical company.

Michael Wood

 Dr. Michael B. Wood, M.D., is Independent Director of Cubist Pharmaceuticals, Inc., since March 2005. Dr. Wood is currently an Orthopedic Surgeon and retired President-emeritus of the Mayo Foundation, a non-profit organization, and Professor of Orthopedic Surgery at the Mayo Clinic School of Medicine. He was previously Chief Executive Officer of the Mayo Foundation from 1999 until 2003. Dr. Wood is also a director of Singapore Health Services, or SingHealth, an integrated health system in Singapore, STERIS Corporation, or STERIS, a public medical device company, and Helix Medical LLC, a private healthcare-related company.

Eileen McIntyre

Insider Trading

Name Shares Traded Price

SOETERS MARTINUS HERMANUS

 995 $0.00

HENNEY JANE E

 995 $0.00

MOULDER LEON O JR

 995 $0.00

LAWTON ALISON FRANCIS

 995 $0.00

CORRIGAN MARK H N

 995 $0.00

HUTSON NANCY J

 1,347 $0.00

LAWTON ALISON FRANCIS

 1,347 $0.00

ROSENBERG MARTIN

 1,347 $0.00

HENNEY JANE E

 1,347 $0.00

SOETERS MARTINUS HERMANUS

 1,347 $0.00

CORRIGAN MARK H N

 1,347 $0.00

SINGLETON J MATTHEW

 1,347 $0.00

WOOD MICHAEL B

 1,347 $0.00

MOULDER LEON O JR

 1,347 $0.00

BATE KENNETH M

 2,075 $0.00

GILMAN STEVEN C

 15,125 $16.76

GILMAN STEVEN C

 15,125 $54.49

BATE KENNETH M

 2,500 $54.95

BATE KENNETH M

 2,500 $11.89

CORRIGAN MARK H N

 14,000 $54.60

CORRIGAN MARK H N

 14,000 $18.22

SINGLETON J MATTHEW

 27,500 $55.48

SINGLETON J MATTHEW

 10,000 $9.56

SINGLETON J MATTHEW

 17,500 $22.71

LARANJEIRA CHARLES ANTHONY

 10,000 $35.90
» Full list on Insider Trading
Search Stocks